



## AMENDMENTS TO THE CLAIMS

1 to 11. (Canceled)

12. (New) A compound represented by the following formula (1), or a salt thereof:



wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents, any adjacent two of which may be bound to one another to form a ring of the formula



said substituents each independently selected from the group consisting of a halogen atom, a halogen substituted or unsubstituted  $C_1$  to  $C_6$  alkyl group, and a halogen substituted or unsubstituted  $C_1$  to  $C_6$  alkoxy group;


R is a  $C_1$  to  $C_6$  alkylsulfonyl group, a  $C_1$  to  $C_6$  alkylcarbonyl group, a  $C_1$  to  $C_6$  alkoxy carbonyl group, or a formyl group;

m is 1 or 2;


n is 2 or 3; and

q is 1 or 2.

13. (New) The compound derivative according to claim 12, represented by the following formula (1a), or a salt thereof:



wherein the ring A is a benzene ring, which may have 1 to 3 substituents, any adjacent two of which may be bound to one another to form a ring of the formula



said substituents each independently selected from the group consisting of a halogen atom, a halogen substituted or unsubstituted  $C_1$  to  $C_6$  alkyl group, and a halogen substituted or unsubstituted  $C_1$  to  $C_6$  alkoxy group;

R is a  $C_1$  to  $C_6$  alkylsulfonyl group, a  $C_1$  to  $C_6$  alkylcarbonyl group, a  $C_1$  to  $C_6$  alkoxy carbonyl group, or a formyl group;

n is 2 or 3; and

q is 1 or 2.

**14. (New)** The compound according to claim 13, or a salt thereof, wherein in formula (1a) above, n is 3.

**15. (New)** The compound according to claim 13, or a salt thereof, wherein in formula (1a) above, R is an acetyl group and n is 3.

**16. (New)** The fused bicyclic pyridine derivative according to claim 13, or a salt thereof, wherein in formula (1a) above, R is an acetyl group, n is 3, and q is 1.

**17. (New)** A tachykinin receptor antagonist composition containing as an effective amount of the compound according to claim 12, or a salt thereof and a carrier.

18. (New) An NK1 receptor antagonist composition containing an effective amount of the compound according to claim 12, or a salt thereof and a carrier.
19. (New) A composition for the prophylactic or therapeutic treatment of dysuria, containing an effective amount of the compound according to claim 12, or a salt thereof and a carrier.
20. (New) The composition according to claim 19 wherein said dysuria is a defective bladder function.
21. (New) The composition according to claim 20 wherein said defective bladder function is increased urinary frequency or incontinence of urine.
22. (New) A composition for the prophylactic or therapeutic treatment of disorders of the digestive tract, containing an effective amount of the compound according to claim 12, or a salt thereof and a carrier.
23. (New) The composition according to claim 22 wherein the disorders of the digestive tract are ulcerative colitis or Crohn's disease.
24. (New) A composition for the prophylactic or therapeutic treatment of vomiting induced by exposure to X-ray, chemotherapy, pregnancy, migraine, postoperative pains, decreased gastrointestinal motility, or side effects of drugs, containing an effective amount of the compound according to claim 12, or a salt thereof and a carrier.
25. (New) A composition for the treatment of asthma, coughing, ache, migraine, tooth pain, or rheumatoid arthritis, containing an effective amount of the compound according to claim 12, or a salt thereof and a carrier.